MedTrace Logo

Treatment of Severe and Critical COVID-19 Pneumonia With Convalescent Plasma

NCT04432103 · Status: TERMINATED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 6

Last updated 2021-08-02

No results posted yet for this study

Summary

Open label two arms, non randomized Convalescent Plasma treatment to severe and critical pneumonia COVID-19 hospitlaized patients compared to a historical cohort with matched controls.

Conditions

Interventions

BIOLOGICAL

Anti SARS-CoV 2 Convalescent Plasma in severe COVID-19 patients

Administration of Convalescent Plasma to COVID-19 obtained from donors with prior documented SARS-CoV 2 infection with IgG antibodies to hospitalized COVID-19 severe cases.

BIOLOGICAL

Anti SARS-CoV 2 Convalescent Plasma in critical COVID-19 patients

Administration of Convalescent Plasma to COVID-19 obtained from donors with prior documented SARS-CoV 2 infection with IgG antibodies to hospitalized COVID-19 critical cases.

Sponsors & Collaborators

  • Centro Medico ABC

    lead OTHER

Principal Investigators

  • Francisco Moreno, MD · ABC Medical Center Internal Medicine Department. Mexico City, Mexico

  • Irma Hoyo, MD PHD · ABC Medical Center Internal Medicine Department. Mexico City, Mexico

  • Benjamín Valente, MD MSc DTMH · ABC Medical Center Internal Medicine Department. Mexico City, Mexico

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-08-08
Primary Completion
2021-01-29
Completion
2021-01-29

Countries

  • Mexico

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04432103 on ClinicalTrials.gov